The European Medicines Agency has recommended Fruzaqla, Truqap, and Eribulin Baxter for use in the treatment of specific colorectal and breast cancers.
Researchers identified a handful of prognostic factors to create a synthetic control arm, which can ultimately replace placebo control arms in future trials of salvage-line metastatic CRC.
Patients with metastatic colorectal cancer who have the KRAS G12C mutation demonstrated improved quality of life following sotorasib and panitumumab compared with standard therapy.